Company profile: Coris BioConcept
1.1 - Company Overview
Company description
- Provider of rapid diagnostic kits, developing, marketing and selling assays including RESIST Range for antibiotic resistance (carbapenemase-producing organisms), Legionella K-SeT lateral flow test for Legionella pneumophila, HAT Sero K-SeT for Trypanosoma brucei gambiense, BL-RED electrochemical test for bacterial hydrolysis related to 3GC antibiotics, Giardia-Strip dipstick test, and RT-LAMP fluorescence assays.
Products and services
- BL-RED: Delivers a rapid electrochemical test identifying bacterial hydrolysis activity related to 3GC antibiotics, measuring hydrolytic enzyme activity quickly with an electrochemical readout
- Giardia-Strip: Supplies a dipstick assay detecting Giardia pathogens, engineered for ease of use and rapid results, supporting quick pathogen identification with minimal handling steps
- HAT Sero K-SeT: Offers a lateral flow test for detecting Trypanosoma brucei gambiense, including necessary sampling devices to streamline specimen collection and support rapid detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Coris BioConcept
Ashvattha Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision nanomedicines and PET imaging agents, developing D-4517.2 for wet AMD and DME, OP-801 targeting CNS macrophages/microglia as a biomarker of neuroinflammation, OP-101 to modulate inflammatory cell activity in severe COVID-19 and other inflammatory diseases, and CSF1R Dendranib, a CSF1R tyrosine kinase inhibitor for multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ashvattha Therapeutics company profile →
Pattern Bioscience
HQ: United States
Website
- Description: Provider of biotech diagnostic solutions to combat antibiotic resistance, including Digital Culture Technology, a single-cell analysis platform using digital cell reactors and machine learning to rapidly diagnose complex bacterial infections and determine antibiotic response without traditional culture, and the Pneumonia Action Panel for fast, comprehensive pathogen identification and susceptibility in hospitalized severe pneumonia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pattern Bioscience company profile →
NRx Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting central nervous system disorders and pulmonary diseases, with investigational products including NRX-101 for suicidal bipolar depression (Phase 3), chronic pain (Phase 2), and PTSD (Phase 2), and NRX-100 (IV ketamine) for severe bipolar depression post stabilization from a suicidal crisis (Phase 3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NRx Pharmaceuticals company profile →
Enantigen
HQ: United States
Website
- Description: Provider of discovery, development, and commercialization of novel drugs for life-threatening infectious diseases, with a primary focus on oral therapeutics for the treatment of hepatitis; located at the Pennsylvania Biotechnology Center.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enantigen company profile →
Abivax
HQ: France
Website
- Description: Provider of clinical-stage biotechnology therapies that mobilize the body's natural immune machinery to treat autoimmune diseases, viral infections, and cancer, including obefazimod for ulcerative colitis (Phase 3), planned Phase 2b for Crohn's disease, exploration as combination therapy for ulcerative colitis in preclinical studies, and nonclinical evaluation for additional chronic inflammatory indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abivax company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Coris BioConcept
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Coris BioConcept
2.2 - Growth funds investing in similar companies to Coris BioConcept
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Coris BioConcept
4.2 - Public trading comparable groups for Coris BioConcept
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →